Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorKaraca, Halit
dc.contributor.authorCiltas, Aydin
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorSevinc, Alper
dc.contributor.authorDemirci, Umut
dc.date.accessioned2024-04-24T17:28:19Z
dc.date.available2024-04-24T17:28:19Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: There is no standard treatment for patients with colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment. Here we aimed to retrospectively evaluate the efficacy and tolerability of raltitrexed in combination with oral 5-fluoropyrimidine (uracil tegafur-UFT) or mitomycin C as salvage therapy in mCRC patients. Materials and Methods: A total of 62 patients who had received raltitrexed combined with UFT or mitomycin C were identified between December 2008 and June 2013. They were given raltitrexed 2.6 mg/m(2) (max 5 mg) i.v. on day 1 in combination with either oral UFT 500 mg/day on days 1-14 every 3 weeks (group A) or mitomycin C 6 mg/m(2) i.v. on day every 3 weeks (group B). Results: Forty-two patients (67.7%) were in group A and 20 (32.2%) in group B. In 15 patients (24%) grade 3/4 toxicity was observed, resulting in dose reduction, and in 13 patients (20.9%) dose delay was necessary. The median progression free survival (PFS) was 3 months (95% CI 2.65-3.34) and median overall survival (OS) was 6 months (95% CI 2.09-9.90) in the whole group. Median PFS was 3 months (95% CI 2.60-3.39) in group A vs 3 months (95% CI 1.64-4.35) in group B (p=0.90). Median OS was 6 months (95% CI 2.47-9.53) in group A vs 12 months (95% CI 2.83-21.1) in group B (p=0.46). Conclusions: The combination of raltitrexed with UFT or mitomycin C seem to be a salvage therapy option due to safety profile and moderate clinical activity in heavily-pretreated mCRC patients.en_US
dc.identifier.doi10.7314/APJCP.2014.15.4.1845
dc.identifier.endpage1849en_US
dc.identifier.issn1513-7368
dc.identifier.issue4en_US
dc.identifier.pmid24641419
dc.identifier.scopus2-s2.0-84896940789
dc.identifier.scopusqualityQ3
dc.identifier.startpage1845en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.4.1845
dc.identifier.urihttps://hdl.handle.net/11468/20399
dc.identifier.volume15en_US
dc.identifier.wosWOS:000333670100062
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRaltitrexeden_US
dc.subjectUracil-Tegafuren_US
dc.subjectMitomycin Cen_US
dc.subjectSalvage Treatmenten_US
dc.subjectColorectal Canceren_US
dc.titleEfficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)en_US
dc.titleEfficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu